Inspira Technologies Oxy BHN Ltd Trading Resumes
Inspira Technologies Oxy BHN Ltd trading resumes
Get Free Real-Time Notifications for Any Stock
Analyst Views on IINN
About IINN
About the author
Inspira Technologies Achieves Major Milestone in U.S. Hospital
- Clinical Evaluation Completed: Inspira's INSPIRA™ ART100 system has completed its clinical evaluation at a leading U.S. academic medical center, successfully treating approximately 30 patients, marking its transition from pilot use to standard clinical workflow and significantly enhancing the company's recognition in the medical device market.
- Procurement Process Initiated: The medical center has initiated an internal procurement process for multiple ART100 systems, indicating that the technology's clinical value and reliability have been thoroughly validated, which is expected to drive broader adoption of ART100 across other healthcare institutions.
- Technology Validation: The ART100 system is the first to progress from clinical evaluation to a budgeted procurement pathway at a major U.S. academic medical center, reflecting Inspira's competitiveness and market potential in the medical device sector, thereby strengthening its commercial positioning.
- Future Development Outlook: Inspira CEO Dagi Ben-Noon stated that this milestone will facilitate the broader adoption of the ART100 platform across leading healthcare institutions, further solidifying the company's market position in life support and MedTech.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
